Social Anxiety Disorder Clinical Trial
Official title:
Randomised Controlled Trial of Cognitive-Behavioural Bibliotherapy (CBB) for Social Anxiety Disorder as a Prelude to High-Intensity Cognitive-Behavioural Therapy (CBT) in a Local IAPT Service.
The efficacy of high-intensity Cognitive-Behavioural Therapy (CBT) for social anxiety
disorder is well established (Mayo-Wilson et al., 2014) and it is recommended by the National
Institute of Health and Clinical Excellence (NICE) as the first-line psychological
intervention for social anxiety disorder. The treatment aims to modify several maintenance
factors (e.g., self-focused attention) that are specified in cognitive models of social
anxiety disorder (e.g., Clark & Wells, 1995).
Cognitive-behavioural self-help treatments for social anxiety disorder have been developed to
overcome various accessibility issues (e.g., long wait-lists, and the patient's need to avoid
social situations, etc) associated with high-intensity CBT (Abramowitz et al., 2009;
Carlbring et al., 2007) but a recent network meta-analysis (Mayo-Wilson et al., 2014)
identified the former as less cost-effective than the later and thus, they are not
recommended as standalone treatments.
However, the potential benefit of cognitive-behavioural self-help treatments for social
anxiety disorder within a stepped-care recovery model as a prelude to high-intensity CBT has
not been formally evaluated.
The aim of this study is to evaluate a seminal Cognitive-Behavioural Bibliotherapy* (CBB;
"pure self-help" book) - 'Overcoming Social Anxiety & Shyness' (Butler, 2009) - for patients
with social anxiety disorder while on the wait-list for high-intensity CBT within an
Improving Access to Psychological Therapies (IAPT) service, and to determine if some patients
recover from CBB alone or whether there may be a reduction in the average number of
high-intensity CBT sessions for those patients who subsequently require further treatment.
The study is funded by Constable & Robinson, Kellogg College (University of Oxford) and
Talking Change (Solent NHS Trust).
* The Reading Well Books on Prescription scheme with funding from the Arts Council England
enables general practitioners (GPs) and mental health professionals to prescribe seminal CBBs
for patients with mood and anxiety disorders. The books are accessed free of charge via local
libraries. The scheme works within NICE guidelines and it is support by the Royal Colleges of
GPs, Nursing and Psychiatrists, the British Association for Behavioural and Cognitive
Psychotherapies and the Department of Health through its IAPT programme.
P A R T I C I P A N T S
Patients will be recruited within an Improving Access to Psychological Therapies (IAPT)
service: 'Talking Change' (Portsmouth). Advertisement for the study will be distributed
locally, through social media and via the 'Talking Change' Internet website.
It is generally accepted that social anxiety disorder is a chronic condition and significant
change in the wait-list does not occur. Hence, because the study aims to explore predicators
of treatment response, a priori power analyses determined that approximately 114 patients
randomly assigned for twelve-weeks at a ratio of 2:1 would provide sufficient power for
statistical analyses; seventy-six and thirty-eight patients in the Cognitive-Behavioural
Bibliotherapy (CBB) and wait-list control (WAIT) group, respectively.
Randomisation will be conducted by someone unassociated with the study using sealed
envelopes.
M E A S U R E S
Risk Assessment:
An IAPT-standard risk assessment will be utilised.
Diagnostic measures:
Diagnostic interviews will use a combination of the Anxiety and Related Disorders Interview
Schedule (ADIS-5; Brown & Barlow, 2014) for the Diagnostic and Statistical Manual of Mental
Disorders (5th ed.; DSM-5; American Psychiatric Association, 2013) to identify social anxiety
disorder and the Structured Clinical Interview for the Diagnostic and Statistical Manual of
Mental Disorders (4th ed.; DSM-4; American Psychiatric Association, 1994) Axis I disorders
(SCID-I; First, Spitzer, Gibbon and Williams, 1995) and Axis II disorders (SCID-II; First,
Gibbon, Spitzer, Williams and Benjamin, 1997). All patients will be assessed with the social
anxiety disorder module of the ADIS, the overview and screener modules of the SCID-I, and the
screener questionnaire for SCID-II. If the SCID-I screener module indicates that another Axis
I disorder might be present, the SCID-I module for that disorder will also be administered.
The same applies to the screener questionnaire for the SCID-II. However, regardless of
screening responses, all patients will also be assessed with the avoidant personality
disorder section of the SCID-II.
The Social Phobia Inventory (SPIN; Connor, 2000) will assess the main spectrum of social
anxiety disorder such as fear, avoidance, and physiological symptoms.
The Adult Reading Test (ART; Everatt, Brooks, & Fidler, 2004) will assess reading accuracy,
reading comprehension, speed of reading and speed of writing.
Primary measures (CBB, CBT and WAIT groups):
IAPT Standard Minimum Data Set (MDS): The brief versions of the Patient Health Questionnaire
(PHQ-9; Kroenke, Spitzer, & Williams, 2001) and the Generalised Anxiety Disorder
Questionnaire (GAD-7; Spitzer, Kroenke, Williams, & Löwe, 2006) will assess mood and
generalised anxiety, respectively. The Work and Social Adjustment Scale (WSAS; Marks, 1986)
will assess functional impairment attributable to an identified problem. The Phobia Scales is
a non-validated phobia screener of social phobia, panic disorder/agoraphobia, and specific
phobia avoidance.
The Social Phobia Inventory (SPIN; Connor, 2000) will assess the main spectrum of social
anxiety disorder such as fear, avoidance, and physiological symptoms.
The Social Participation & Satisfaction Questionnaire (SPSQ; Alden & Taylor, 2011) will
assess the degree by which the participant is participating is social activity, and
relationship satisfaction.
Secondary measures (CBB, CBT and WAIT groups):
The self-report version of the Liebowitz Social Anxiety Scale (LSAS-SR; Baker, Heinrich, Kim,
& Hofmann, 2002; Liebowitz, 1987) will assess social anxiety and the frequency of avoidance.
The Self-Focused Attention Scale (SFA; Bögels, Alberts, & de Jong, 1996) will assess the
degree by which the participant engages in self-focused attention.
The Social Behaviour Questionnaire (SBQ; Clark et al., 2006) will assess the frequency by
which the participant engages in a range of common safety-seeking behaviours.
The Social Phobia Cognitions Questionnaire (SPC; Clark et al., 2006) will assess the
frequency and belief ratings for a range of typical cognitions in social anxiety.
The Anticipatory Processing Questionnaire (APQ; Vassilopoulos, 2004) and the Post-Event
Processing Questionnaire-Revised (PEPQ-R; McEvoy & Kingsep, 2006) will assess the degree by
which the participant engages in pre- and post-event rumination.
Weekly measures [CBB and CBT groups only]:
IAPT Standard Minimum Data Set (MDS): The brief versions of the Patient Health Questionnaire
(PHQ-9; Kroenke, Spitzer, & Williams, 2001) and the Generalised Anxiety Disorder
Questionnaire (GAD-7; Spitzer, Kroenke, Williams, & Löwe, 2006) will assess mood and
generalised anxiety, respectively. The Work and Social Adjustment Scale (WSAS; Marks, 1986)
is a self-report scale of functional impairment attributable to an identified problem. The
Phobia Scales is a non-validated phobia screener of social phobia, panic
disorder/agoraphobia, and specific phobia avoidance.
The self-report version of the Liebowitz Social Anxiety Scale (LSAS-SR; Baker, Heinrich, Kim,
& Hofmann, 2002; Liebowitz, 1987) will be administrated weekly to assess social anxiety and
the frequency of avoidance.
The Social Phobia Inventory (SPIN; Connor, 2000) will assess the main spectrum of social
anxiety disorder such as fear, avoidance, and physiological symptoms.
A written answer to the question "What have I learnt?" will assess treatment compliance.
Qualitative measure (if received CBB):
A semi-structured interview of patients' experiences.
Other measures:
The number of high-intensity CBT sessions required following CBB will be recorded.
P R O C E D U R E
Patients will engage with a brief telephone Triage Assessment of their presenting problems
and will complete the primary measures to assess symptoms of social anxiety, depression,
generalised anxiety, phobia avoidance, general functioning, and social functioning.
Patients will be "stepped-up" to a full face-to-face Step Three Assessment of their
presenting problems if their condition is chronic and cannot be appropriately treated with a
Step 2 intervention. Thus, potential cases of social anxiety disorder who score within the
clinical range (≥19 points) on the SPIN (Connor, 2000) will be "stepped-up". All other cases
will be offered alternative treatment within the service or referred elsewhere as required.
Patients will complete the diagnostic measures to determine social anxiety disorder, a
measure of reading and writing ability, the primary measures again, and the secondary
measures to assess the maintenance factors that are specified in cognitive models of social
anxiety disorder (e.g., Clark & Wells, 1995). Patients who do not meet the inclusion criteria
will be offered alternative treatment within the service or referred elsewhere as required.
Patients who consent to their participation in the study will be randomly allocated to CBB or
WAIT for twelve weeks. The wait-list group will begin high-intensity CBT at postWAIT.
Patients who are not "CBB responders"* will receive high-intensity CBT at postCBB whereas
those who are will be discharged from the service, offered alternative treatment within the
service if "caseness"** remains, or referred elsewhere as required.
The primary and secondary measures will be completed again at preCBB-WAIT-CBT,
midCBB-WAIT-CBT, postCBB-WAIT-CBT, and CBB-CBT one-month follow-up. The CBB and CBT group
will complete the primary measures weekly complete and weekly measures of social anxiety. The
CBB group only will complete a weekly measure of treatment compliance.
Patients will the complete diagnostic measures to determine social anxiety disorder, the
primary measures and the secondary measures again at postCBB-WAIT-CBT and CBB-CBT one-month
follow-up. A qualitative measure of patients' experiences of treatment will be obtained at
postCBB, and postCBT if they previously received CBB.
Patients will be notified when measures must be completed; most of which are completed online
a secure and encrypted Internet website and some of which are completed face-to-face.
The CBB group will be provided with a self-help book ('Overcoming Social Anxiety & Shyness';
Butler, 2009) by local libraries and encouraged to work through in a twelve-week period. A
suggested timetable for completing the "pure self-help" treatment will be provided. Clinical
or non-clinical contact will not be provided. The CBT group will receive up to fourteen
face-to-face sessions of high-intensity CBT at their local clinic.
Patients will be provided the Chief Investigator's contact details should they wish to
discuss any aspect of the study or if they become distressed. If patients' risk status should
change during the trail they will be instructed to contact the Chief Investigator
immediately.
At the end of study all patients will be discharged from the service, offered alternative
treatment within the service if "caseness" remains, or referred elsewhere as required.
* Those patients who have a statistically reliable improvement that place their mean LSAS-SR
score within the range (mean ± two standard deviations) of the non-clinical population mean,
who score ≤ 18 points on the SPIN (Connor, 2000), and who no longer meet full DSM-V criteria
for social anxiety disorder (APA, 2013) will be "CBB responders" (i.e., a clinically
significant change; see Jacobson & Truax, 1991). The non-clinical population mean will be
based on Fresco et al.'s (2001) non-anxious control group.
** The IAPT programme defines "caseness" as ≤ 9 points on the PHQ-9 (Kroenke, Spitzer, &
Williams, 2001) and ≤ 7 points on the GAD-7 (Spitzer, Kroenke, Williams, & Löwe, 2006).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06274112 -
Using TMS to Understand Neural Processes of Social Motivation
|
N/A | |
Completed |
NCT02554929 -
Treatment of Social Anxiety Disorder and Selective Mutism
|
N/A | |
Completed |
NCT00684541 -
Interpretation Modification Program for Social Phobia
|
N/A | |
Completed |
NCT00684320 -
Attention Disengagement Training for Social Phobia
|
N/A | |
Completed |
NCT03247075 -
Internet-delivered CBT vs Internet-delivered Support and Counseling for Youth With Social Anxiety Disorder - An RCT
|
N/A | |
Completed |
NCT02811458 -
Clinical Trial of Transdiagnostic Cognitive-Behavior Therapy for Anxiety Disorders
|
N/A | |
Withdrawn |
NCT04622930 -
Waitlist-Control Trial of Smartphone CBT for Social Anxiety Disorder (SAD)
|
N/A | |
Active, not recruiting |
NCT05018312 -
Modified Collaborative Assessment VS Standard Assessment on Readiness For Psychotherapy Among Patients With Anxiety
|
N/A | |
Active, not recruiting |
NCT05124639 -
Clinical Trial of a Group Self-management Support Program for Anxiety Disorders
|
N/A | |
Completed |
NCT05858294 -
The Safety, Acceptability and Efficacy of Alena
|
N/A | |
Active, not recruiting |
NCT05600114 -
Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder
|
Phase 2 | |
Not yet recruiting |
NCT06081348 -
Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
|
Phase 2 | |
Not yet recruiting |
NCT02924610 -
Brief Intervention to Reduce Fear
|
Phase 4 | |
Active, not recruiting |
NCT02592564 -
Brain Plasticity and Cellular Aging After Internet-delivered CBT for Social Anxiety Disorder
|
N/A | |
Recruiting |
NCT02305537 -
Building an Outcomes Assessment Infrastructure to Assess Anxiety Treatment
|
N/A | |
Terminated |
NCT03764644 -
Web-based Attention Bias Modification Treatment for Childhood Anxiety Disorders
|
N/A | |
Unknown status |
NCT01712321 -
Study of Vilazodone to Treat Social Anxiety Disorder
|
N/A | |
Completed |
NCT01320800 -
CBT for Social Anxiety Disorder Delivered by School Counselors
|
Phase 2 | |
Completed |
NCT00872820 -
Examining Long-Term Effects and Neural Mediators of Behavioral Treatments for Social Anxiety Disorder
|
N/A | |
Completed |
NCT00485615 -
An Open Label Trial of Omega 3(o3mega+Joy)in the Treatment of Social Phobia
|
Phase 2 |